During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune checkpoint inhibitor regimens in melanoma including alternate dosing strategies.
Of Interest
New melanoma therapy prevents brain metastasis in preclinical studies
A government-funded research team has identified focal adhesion kinase (FAK) as a key driver of melanoma metastasis to the brain. This discovery could revolutionise treatment by not only addressing the condition but also preventing its spread to the brain.
Bevacizumab Addition May Be Beneficial for Melanoma Brain Metastases, Study Suggests
Bevacizumab (Avastin) was safely added to pembrolizumab (Keytruda) in patients with active melanoma brain metastases who had not previously received a PD-1 inhibitor, according to data from a small phase 2 trial published in the Journal of Clinical Oncology.
Novel radiosurgical platform to treat a case of uveal melanoma
Uveal melanoma, which primarily affects Caucasian patients, is the most common primary intraocular tumor in adults2 that most often affects the choroid (90%), ciliary body (6%), and iris (4%)